|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Identification of CTRP1 as a Prognostic Biomarker and Oncogene in Human Glioblastoma.
|
31183364 |
2019 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Inhibition of CTRP1 may inhibit the pathogenesis of atherosclerosis at early stage.
|
28625919 |
2017 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Inhibition of CTRP1 may inhibit the pathogenesis of atherosclerosis at early stage.
|
28625919 |
2017 |
|
Childhood Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Identification of CTRP1 as a Prognostic Biomarker and Oncogene in Human Glioblastoma.
|
31183364 |
2019 |
|
Cholestasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
CTRP1 correlated strongly with markers of inflammatory response, renal function, liver damage and cholestasis.
|
31083558 |
2019 |
|
Chronic Kidney Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
No significant association was found between CTRP1 levels and CKD stage, presence of diabetes, aldosterone and renin levels, or blood pressure.
|
31198543 |
2019 |
|
Congestive heart failure
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
There were no differences in the CTRP1 levels in cardiomyocytes between the CHF group and the non-CHF group.
|
28810263 |
2017 |
|
Congestive heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results demonstrated that C1QTNF1 improves cardiac function and inhibits cardiac hypertrophy and fibrosis by increasing and activating AMPKa, suggesting that C1QTNF1 could be a therapeutic target for cardiac hypertrophy and heart failure.
|
29733904 |
2018 |
|
Coronary Arteriosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Association of C1q/TNF-related protein-1 (CTRP1) serum levels with coronary artery disease.
|
31081425 |
2019 |
|
Coronary Artery Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We measured CTRP1 serum levels in 539 patients undergoing coronary angiography for the evaluation of established or suspected stable coronary artery disease (CAD).
|
31051410 |
2019 |
|
Coronary Artery Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Serum levels of CTRP1 were significantly higher in CAD patients than in controls (17.24 ± 1.07 versus 9.31 ± 0.56 ng/mL), and CTRP1 levels increased with increasing severity of CAD.
|
31081425 |
2019 |
|
Coronary heart disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Association of C1q/TNF-related protein-1 (CTRP1) serum levels with coronary artery disease.
|
31081425 |
2019 |
|
Dehydration
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Mice lacking Ctrp1 fail to maintain normotension under dehydration conditions, resulting in hypotension, suggesting that CTRP1 is an essential protein for maintaining blood pressure homeostasis.
|
30463644 |
2018 |
|
Dehydration
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
The increase in CTRP1 under dehydration conditions was mediated by glucocorticoids, and the antagonist mifepristone prevented the increase in CTRP1 and attenuated BP recovery.
|
30030219 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
Biomarker
|
disease |
BEFREE |
CTRP1 is a novel adipokine associated with T2DM in humans.
|
24827430 |
2014 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our data supports CTRP1 and CTRP12 as potential novel biomarkers for the prediction and early diagnosis of T2DM.
|
28207876 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
Biomarker
|
disease |
BEFREE |
C1qTNF-related protein 1 (CTRP1) is independently associated with type 2 diabetes.
|
28674284 |
2017 |
|
Glioblastoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The genetic alterations of CTRP1 occurred at a low rate in GBM (2 of 591 sequenced cases/patients, 0.33%).
|
31183364 |
2019 |
|
Glioblastoma Multiforme
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The genetic alterations of CTRP1 occurred at a low rate in GBM (2 of 591 sequenced cases/patients, 0.33%).
|
31183364 |
2019 |
|
Heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results demonstrated that C1QTNF1 improves cardiac function and inhibits cardiac hypertrophy and fibrosis by increasing and activating AMPKa, suggesting that C1QTNF1 could be a therapeutic target for cardiac hypertrophy and heart failure.
|
29733904 |
2018 |
|
Hypertensive disease
|
0.020 |
Biomarker
|
group |
BEFREE |
As CTRP1 was highly expressed in obese subjects as well as up-regulated in hypertensive patients, CTRP1 may be a newly identified molecular link between obesity and hypertension.
|
18171693 |
2008 |
|
Hypertensive disease
|
0.020 |
AlteredExpression
|
group |
LHGDN |
As CTRP1 was highly expressed in obese subjects as well as up-regulated in hypertensive patients, CTRP1 may be a newly identified molecular link between obesity and hypertension.
|
18171693 |
2008 |
|
Hypertensive disease
|
0.020 |
Biomarker
|
group |
BEFREE |
Patients with hypertension also display higher circulating CTRP1 levels, compared to healthy individuals, indicating that excessive CTRP1 may affect development of hypertension.
|
30463644 |
2018 |
|
Kidney Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
High CTRP1 levels may have a renal protective role since they were associated with slower kidney disease progression.
|
31198543 |
2019 |
|
Liver diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
CTRP1 in Liver Disease.
|
28212710 |
2017 |